Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to Advance the Development of Rare Disease Therapeutics
News release excerpt provided by PR Newswire.
Takeda Pharmaceutical Company Limited (TSE: 4502), and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio have announced a multi-year collaboration to accelerate breakthrough therapeutic discoveries in rare diseases.
A first of a kind partnership for Harrington Discovery Institute with a major pharmaceutical company, this collaboration with Takeda will build on Harrington Discovery Institute’s established operating model to create a new program specifically for the advancement of medicines for rare diseases. At the same time, this collaboration will complement Takeda’s strategic R&D focus in its therapeutic areas of oncology, gastroenterology and central nervous system disorders. The new Harrington program will focus on M.D. and Ph.D. researchers from across the United States, developing disruptive and transformative research, which shows promise for translation into novel treatments.
Click here to read the complete release, and read more in Crain’s Cleveland Business.
Originally published April 27, 2017.
Leave a Reply